Sign In
NewsRadar

Affimed Therapeutics AG

Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The company's research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allow Affimed to identify antibodies against even the most difficult of targets.

• Show past press releases
• Edit this company

Elevator Pitch
To be the leader in antibody research, Affimed has assembled one of the industry's most powerful research engines as a formidable resource for in-house antibody discovery. The core of this technology comprises three distinct antibody libraries that can be screened using phage display to identify antibodies to address even the most difficult of targets.

Contact Information
Address:
 
 

Phone:
Fax:
Web:
Contact:
 
 
Technologiepark
Im Neuenheimer Feld 582
Heidelberg 69120
Germany
+49 (0)6221 65307 0
+49 (0)6221 65307 77
http://www.affimed.com
Dr. Rolf H. Günther
+49 (0)6221 65307 0

Company Facts
Founded:May 2000
Founders:Prof. Dr. Melvyn Little
CEO:Dr. Rolf H. Günther
CTO or technical lead:Prof. Dr. Melvyn Little
CFO or finance director:Dr. Florian Fischer
Head of Sales:n/a
Head of Marketing:Northbank Communications

Stage:Public
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:23
Profitability:Pre-revenue
Funding raised:Yes
Funding sought:Yes
Seeking Partnerships:Yes

Non-executive Board Members

  • Gerhard Ries
  • Frank Mühlenbeck
  • Michael Sheffery
  • Mark Wegter

    Key Customers

  • Not Available

    Key Business Partners

  • Not Available

    Key Competitors

  • Not Available

    Capital Raised
    DateSizeInvestors
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    Public Offerings
    DateTypeExchange
    No public offerings


  • Data


    26,261
    Tech investments
    From our Online Data Service
    16,961
    VC-backed companies
    From our Radar


    Recent Deals


    DATEAMOUNTSECTOR
    Oct 19€3.0MInternet services
    Oct 19€6.0MBusiness applications
    Oct 18€11.0MConsumer electronics
    Oct 18€5.0MBusiness applications
    Oct 18€2.3MInternet services
    Oct 17€5.9MBiopharmaceuticals
    Oct 16€51.0MArtificial Intelligence

    For information on Europe's most extensive database on technology funding click here!

    Events



    Press Releases


    May 28
    Identiq
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    Nethone
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises 1m in seed funding to build tech-enabled home ...





    About usContact usLegal Information
    Copyright 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.